Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
University of Pennsylvania
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07594067CT.gov TCR1188-ABC Cells in KRAS-mutated Cancers | — | Not Yet Recruiting | — | — | — |
NCT05769959CT.gov Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | — | Terminated | — | — | — |
NCT03193190CT.gov A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tocilizumab (this asset) | University of Pennsylvania | P1/2 | CCC · 51 |
| Fluorouracilum | Jonsson Comprehensive Cancer Center | P4 | BBB |
| Docetaxel | Bristol-Myers Squibb | P2 | BBB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| Irinotecan | Jonsson Comprehensive Cancer Center | P3 | BB |
| Capecitabine | Zhejiang University | P4 | BB |
| Olaparib | Lantern Pharma Inc. | P3 | BB |
| Irinotecan Sucrosofate | SWOG Cancer Research Network | P3 | BB |
| Daraxonrasib | Revolution Medicines, Inc. | P3 | BB |
+42 more in the Pancreatic Adenocarcinoma cohort
Other indications for Tocilizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rheumatoid Arthritis | — | P3 | BB · 66 |
| COVID-19 | — | P3 | BB · 65 |
| Acute Chest Syndrome | — | P3 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tocilizumab in Pancreatic Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tocilizumab-pancreatic-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →